The abstract is read at the publisher; the summary is JClub's.
TetprM-E mRNA-LNP vaccination in mice elicits neutralizing titers >1:1500 against DENV1-4, with env-binding antibodies persisting for 34 weeks and no measurable in vitro ADE.
- Why it matters: Dengue vaccines must generate durable, four-serotype immunity while avoiding antibody-dependent enhancement and countering immune imprinting from prior exposure.
- What they did: Mice received tetravalent LNP-formulated nucleoside-modified mRNAs encoding DENV1-4 prM-E antigens using three immunization strategies, then neutralization, CD4-dependent germinal-center responses, CD8+ T cells, memory B cells, and ADE were assessed.
- The result: Immune sera transferred to immunocompromised mice gave 100% survival and reduced viremia after lethal DENV2 challenge, and vaccination broadened neutralization across DENV1-4 despite monovalent priming bias.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.